Dinesh Patel
Chief Executive Officer at PROTAGONIST THERAPEUTICS, INC.
Net worth: 14 M $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Chaitan S. Khosla | M | 59 |
Protagonist Pty Ltd.
Protagonist Pty Ltd. Pharmaceuticals: MajorHealth Technology Protagonist Pty Ltd. operates as a clinical-stage biopharmaceutical company. Its proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded on September 19, 2001 and is headquartered in Brisbane, Australia. | 7 years |
Harold Selick | M | 69 |
Protagonist Pty Ltd.
Protagonist Pty Ltd. Pharmaceuticals: MajorHealth Technology Protagonist Pty Ltd. operates as a clinical-stage biopharmaceutical company. Its proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded on September 19, 2001 and is headquartered in Brisbane, Australia. | 15 years |
Samuel Saks | M | 69 | - | |
William Waddill | M | 67 |
Protagonist Pty Ltd.
Protagonist Pty Ltd. Pharmaceuticals: MajorHealth Technology Protagonist Pty Ltd. operates as a clinical-stage biopharmaceutical company. Its proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded on September 19, 2001 and is headquartered in Brisbane, Australia. | 8 years |
Julie Grant | F | 41 |
Protagonist Pty Ltd.
Protagonist Pty Ltd. Pharmaceuticals: MajorHealth Technology Protagonist Pty Ltd. operates as a clinical-stage biopharmaceutical company. Its proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded on September 19, 2001 and is headquartered in Brisbane, Australia. | 3 years |
Richard J. White | M | 82 |
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | 39 years |
Bryan Giraudo | M | 48 | 6 years | |
Sandra Leung | F | 63 | 32 years | |
Lewis Williams | M | 74 | 7 years | |
Sarah O'Dowd | F | 74 | 4 years | |
Ashok Bhandari | M | - | 22 years | |
Asif Ali | M | 50 | 2 years | |
Mohammad Masjedizadeh | M | - | 7 years | |
Carena Spivey | F | - | - | |
Carter J. King | M | 52 | 6 years | |
Suneel Gupta | M | 66 | 5 years | |
Daniel Swisher | M | 61 | 1 years | |
Arturo Molina | M | 65 | 2 years | |
Matthew M. Gosling | M | 53 | 4 years | |
Craig Ostroff | M | - | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Peter R. Dolan | M | 68 | 18 years | |
Steven B. Ratoff | M | 81 | 16 years | |
Sarah Noonberg | M | 56 | 6 years | |
Armen Shanafelt | M | 64 |
Protagonist Pty Ltd.
Protagonist Pty Ltd. Pharmaceuticals: MajorHealth Technology Protagonist Pty Ltd. operates as a clinical-stage biopharmaceutical company. Its proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded on September 19, 2001 and is headquartered in Brisbane, Australia. | 9 years |
Mark L. Smythe | M | - | 16 years | |
Thomas O'Neil | M | 59 | 3 years | |
Donald Kalkofen | M | 60 | 3 years | |
Mark W. Durand | M | 64 | 17 years | |
Priya Jambhekar | F | - | 3 years | |
Eric M. Gordon | M | 78 |
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | 1 years |
Jami Taylor | M | - | 2 years | |
Harrison Bains | M | 80 | 16 years | |
Timothy Meeker | M | 77 | 13 years | |
Dov Goldstein | M | 56 |
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | 15 years |
Lawrence Hamilton | M | 66 | 8 years | |
Matthew Ros | M | 57 | 17 years | |
Robert Peach | M | 68 | 9 years | |
Paul Truex | M | 55 |
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | 1 years |
Dawn Chen | M | - |
Arête Therapeutics, Inc.
Arête Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Arête Therapeutics, Inc. develops and commercializes molecule drugs to treat cardiovascular and inflammatory diseases. It focuses on developing AR9281, an orally-administered compound that inhibits s-EH (soluble epoxide hydrolase), an enzyme that plays a key role in the metabolism of arachidonic acid. It also focuses on testing various back-up candidates as additional first-in-class anti-hypertensive plus agents. The company was founded in 2003 and is headquartered in Hayward, CA. | - |
Paul Herbert Chew | M | 72 | 9 years | |
Charles M. Urbain | M | 70 | 14 years | |
Raymond T. Keane | M | 65 | 20 years | |
Peter Nicklin | M | 61 | 14 years | |
Larry K. Benedict | M | 63 | 7 years | |
Richard Colonno | M | 74 | 16 years | |
George F. Horner | M | 80 |
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | 9 years |
Martin Stogniew | M | 69 |
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | - |
D. Euan MacIntyre | M | - |
Arête Therapeutics, Inc.
Arête Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Arête Therapeutics, Inc. develops and commercializes molecule drugs to treat cardiovascular and inflammatory diseases. It focuses on developing AR9281, an orally-administered compound that inhibits s-EH (soluble epoxide hydrolase), an enzyme that plays a key role in the metabolism of arachidonic acid. It also focuses on testing various back-up candidates as additional first-in-class anti-hypertensive plus agents. The company was founded in 2003 and is headquartered in Hayward, CA. | 2 years |
David S. Krause | M | - |
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | 3 years |
Gerald Crabtree | M | 83 | 7 years | |
Richard S. Shames | M | - | 4 years | |
Paula O’Connor | M | - | - | |
Benjamin Winograd | M | 63 | 9 years | |
Robert E. Allen | M | - | 21 years | |
Niall Murphy | M | 50 | 1 years | |
Lucio Tozzi | M | 60 | 4 years | |
Kirsten Detrick | F | 59 | 13 years | |
Scott Plevy | M | - | 3 years | |
Mitchell P. Cybulski | M | 77 | 6 years | |
Thamil Annamalai | F | - | 3 years | |
Murdo Gordon | M | - | 29 years | |
Ning Yan | M | - | 7 years | |
James E. Shiah | M | 64 | 3 years | |
Steve Carchedi | M | 62 | 9 years | |
Larry Mallis | M | - | - | |
John Golubieski | M | 59 | 16 years | |
William Hodder | M | - | - | |
Sharon Real | M | 60 | 3 years | |
John Hamer | M | 66 |
Arête Therapeutics, Inc.
Arête Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Arête Therapeutics, Inc. develops and commercializes molecule drugs to treat cardiovascular and inflammatory diseases. It focuses on developing AR9281, an orally-administered compound that inhibits s-EH (soluble epoxide hydrolase), an enzyme that plays a key role in the metabolism of arachidonic acid. It also focuses on testing various back-up candidates as additional first-in-class anti-hypertensive plus agents. The company was founded in 2003 and is headquartered in Hayward, CA. | 3 years |
Bruce Wendel | M | 70 | 14 years | |
Nicholas Landekic | M | 65 | 3 years | |
William Jones | M | 60 | 12 years | |
Timothy McNamara | M | 67 | 9 years | |
Samuel Moed | M | 62 | 32 years | |
Julius A. Vida | M | 95 | 18 years | |
Stephen Sadove | M | 72 | 10 years | |
Robert Francis Doman | M | 74 | 8 years | |
Kenneth E. Weg | M | 85 | 10 years | |
John D. Macomber | M | 96 | 5 years | |
William R. Miller | M | 95 | 27 years | |
Barry Wilson | M | 80 | 13 years | |
Frederick B. Oleson | M | - | 9 years | |
Nicole Onetto | M | 71 | 6 years | |
Louis T. DiFazio | M | 86 | 7 years | |
Thomas Hess | M | 60 |
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | 2 years |
Robert A. Ashley | M | 66 | 5 years | |
Henry Y. Pan | M | 77 | 7 years | |
Robert L. Simon | M | 79 | 13 years | |
Mark E. McGovern | M | 70 | 11 years | |
Robert B. Ross | M | - | 3 years | |
Jeffrey Hatfield | M | 66 | 19 years | |
Patrick Colin | M | - | - | |
Jane A. Kramer | F | 68 | 11 years | |
Tracy M. Woody | F | 54 | 2 years | |
Patrick J. Fortune | M | 77 | 3 years | |
Tim Tyson | M | 71 | 8 years | |
Patricia A. Murphy | F | 65 | - | |
Charles Rowland | M | 65 | 8 years | |
Shu Hui Chen | M | 61 | 5 years | |
James New | M | 70 | 12 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 100 | 100.00% |
Australia | 5 | 5.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Dinesh Patel
- Personal Network